Digibind is administered intravenously, usually as a slow infusion. The dose is calculated based on the estimated amount of digoxin in the body, which can be derived from serum digoxin levels and the patient's weight. In acute overdose cases, the dose is often estimated using standardized charts. The infusion should be administered in a controlled setting, such as a hospital, where the patient can be closely monitored for adverse reactions and efficacy.
